

1 Ful 1614

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to:
MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Dated: April 2, 2007 Signature: *Mary Jane DiPalma*
(Mary Jane DiPalma)

Docket No.: GPCI-P02-191
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bockovich et al.

Application No.: 10/584,485

Confirmation No.: 3055

Filed: June 23, 2006

Art Unit: 1614

For: INHIBITORS OF CYCLIN-DEPENDENT
KINASES, COMPOSITIONS AND USES
RELATED THERETO

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. GPCI-P02-191. A duplicate copy of this paper is enclosed.

Dated: April 2, 2007

Respectfully submitted,


By 

David P. Halstead, Ph.D.

Registration No.: 44,735

FISH & NEAVE IP GROUP, ROPES & GRAY
LLP

One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/584,485
				Filing Date	June 23, 2006
				First Named Inventor	Nicholas Bockovich
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	GPCI-P02-191

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-2,969,383	06-20-1961	Flores et al.	
/KC/	AB	US-3,211,731	10-12-1965	Schmidt et al.	
/KC/	AC	US-3,211,732	10-12-1965	Schmidt et al.	
	AD	US-5,593,356	01-14-1997	Takeda	
/KC/	AE	US-5,593,997	01-14-1997	Dow et al.	
/KC/	AF	US-6,291,504	09-18-2001	Nugiel et al.	
/KC/	AG	US-6,407,103	06-18-2002	Nugiel et al.	
/KC/	AH	US-6,413,957	07-02-2002	Nugiel et al.	
/KC/	AI	US-2001/0027195	10-04-2001	Nugiel et al.	
/KC/	AJ	US-2003/0165873	09-04-2003	Come et al.	
/KC/	AK	US-2004/0043388	03-04-2004	Come et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/KC/	BA	WO-94/13677	06-23-1994			
/KC/	BB	WO-98/05335	02-12-1998			
/KC/	BC	WO-99/54308	10-28-1999			
/KC/	BD	WO-00/21926	04-20-2000			
/KC/	BE	WO-02/067654	09-06-2002			
/KC/	BF	WO-02/070662	09-12-2002			
	BG	WO-02/093209	11-21-2002			
/KC/	BH	WO-02/34721	05-02-2002	Du Pont Pharm Co		
/KC/	BI	WO-02/40182	05-23-2002			
/KC/	BJ	WO-02/44174	06-06-2002			
/KC/	BK	WO-03/004491	01-16-2003			
/KC/	BL	WO-03/033499	04-24-2003	GPC Biotech Inc.		
/KC/	BM	WO-03/063764	08-07-2003			
/KC/	BN	EP-0203679	12-03-1986			
/KC/	BO	JP-60-130521	07-12-1985	Toshiyasu		
/KC/	BP	JP-62-099361	05-08-1987	Yoshio, et al		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KC/	CA	Mosher et al., "Benzene Ring Substituted Indeno[1,2-c]pyrazol-4(1H)-ones," J. Org. Chem. 35(11):3685-3688 (1970)	

Examiner Signature	/Karen Cheng/	Date Considered	01/18/2011
--------------------	---------------	-----------------	------------



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/584,485
				Filing Date	June 23, 2006
				First Named Inventor	Nicholas Bockovich
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	GPCI-P02-191

/KC/	CB	Nugiel et al., "Indenopyrazoles as Novel Cyclin Dependent Kinase (CDK) Inhibitors," J. Med. Chem. 44:1334-1336 (2001)	
/KC/	CC	Nugiel et al., "Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 2. Probing the Indeno Ring Substituent Pattern," J. Med. Chem. 45:5524-5232 (2002)	
/KC/	CD	Yue et al., "Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 3. Structure Activity Relationships at C3 (1,2)," J. Med. Chem. 45:5233-5248 (2002)	
/KC/	CE	Shaw et al., "Purines, Pyrimidines and Imidazoles...", Chemical Abstracts Abstract No. 5837, 75(1) (1971)	
/KC/	CF	"Protein Kinase Targets: Strategies for Drug Development," Conference Presentation June 10-11, 2003 Westin Copley Place Hotel, Boston, MA	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Karen Cheng/	Date Considered	01/18/2011
--------------------	---------------	-----------------	------------